News & Media Press Release Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer > Press Release Remix Therapeutics Appoints Matthew R. Patterson as Executive Chairman of its Board of Directors > Press Release Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing > Media Contact Lissette Steele Verge Scientific Communications 202.930.4762 lsteele@vergescientific.com Media Contact Lissette Steele Verge Scientific Communications 202.930.4762 lsteele@vergescientific.com
